Shree Ganesh Remedies Ltd
BSE:540737
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (5.9), the stock would be worth ₹703.78 (38% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.3 | ₹510.75 |
0%
|
| 3-Year Average | 5.9 | ₹703.78 |
+38%
|
| 5-Year Average | 5.7 | ₹687.41 |
+35%
|
| Industry Average | 3.6 | ₹427.21 |
-16%
|
| Country Average | 3.3 | ₹390.37 |
-24%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Shree Ganesh Remedies Ltd
BSE:540737
|
6.6B INR | 4.3 | 36.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 31.1 | 40 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 6.7 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.6B GBP | 5.8 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 6 | 19.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 5.2 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 6 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 1.7 | 19.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 6.3 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 2.1 |
| Median | 3.3 |
| 70th Percentile | 5.5 |
| Max | 4 699.1 |
Other Multiples
Shree Ganesh Remedies Ltd
Glance View
Shree Ganesh Remedies Ltd. engages in the research, development, manufacture, and marketing of healthcare products. The company is headquartered in Ankleshwar, Gujarat. The company went IPO on 2017-10-13. The firm is a supplier of pharmaceutical intermediates and specialty chemicals with chlorination, grignard reaction, hydrogenation and high-vacuum distillation. Its products include intermediates by active pharmaceutical ingredient (API), and fine and specialty chemicals. The company offers services, including customized chemistry and manufacturing, assets and infrastructure and key technologies and expertise. The company also delivers service of contract manufacturing for chemical reactions like amination, amidation, alkylation, bromination, catalytic hydrogenation and chlorination. The firm's subsidiaries include Akshar Jyot Private Limited and Dhari Chemicals Limited.
